CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-
Go back to CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-| (NASDAQ: CRVO) | Delayed: 2.45 +0.01 (0.41%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.44 | 52 Week High | $ | |||
| Open | $2.49 | 52 Week Low | $ | |||
| Day High | $2.61 | P/E | N/A | |||
| Day Low | $2.37 | EPS | $ | |||
| Volume | 132,043 | |||||

